Nuveen Asset Management LLC Sells 105,170 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Nuveen Asset Management LLC lessened its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 28.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 260,697 shares of the company's stock after selling 105,170 shares during the quarter. Nuveen Asset Management LLC owned about 0.26% of Intellia Therapeutics worth $3,040,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. ARK Investment Management LLC increased its stake in Intellia Therapeutics by 2.3% during the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company's stock valued at $146,174,000 after purchasing an additional 280,946 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Intellia Therapeutics by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company's stock valued at $118,816,000 after buying an additional 562,249 shares during the last quarter. Regeneron Pharmaceuticals Inc. bought a new stake in shares of Intellia Therapeutics during the fourth quarter worth about $43,177,000. Geode Capital Management LLC raised its holdings in shares of Intellia Therapeutics by 2.0% in the 4th quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company's stock worth $27,865,000 after acquiring an additional 45,930 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in Intellia Therapeutics by 36.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,976,212 shares of the company's stock valued at $23,042,000 after acquiring an additional 528,962 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently commented on NTLA shares. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $13.00 price objective (down from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. Canaccord Genuity Group dropped their price objective on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating on the stock in a research note on Tuesday. Wall Street Zen raised shares of Intellia Therapeutics to a "sell" rating in a report on Monday, March 3rd. Wedbush reiterated a "neutral" rating and issued a $7.00 price objective (down previously from $10.00) on shares of Intellia Therapeutics in a research note on Thursday, May 29th. Finally, Wells Fargo & Company lowered their target price on Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Intellia Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $34.95.

Intellia Therapeutics Stock Up 6.7%

Shares of NTLA stock traded up $0.51 on Friday, reaching $8.09. The company's stock had a trading volume of 7,207,575 shares, compared to its average volume of 2,757,291. The company has a market capitalization of $837.99 million, a P/E ratio of -1.49 and a beta of 2.33. The stock's 50 day simple moving average is $7.93 and its 200-day simple moving average is $10.06. Intellia Therapeutics, Inc. has a 12-month low of $5.90 and a 12-month high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.26) by $0.16. The company had revenue of $16.63 million for the quarter, compared to the consensus estimate of $11.39 million. The business's revenue was down 42.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.12) earnings per share. Research analysts expect that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.